PubMed Health⌕ Search

Biomedical subjects

L M Gorilovskiĭ

Publications and source records attributed to L M Gorilovskiĭ.

At least 19 recordsLinked to original sources
PubMed1987

[Incidence and nature of metastases of prostatic cancer based on autopsy data].

Pathways of lymphatic and hematogenic spread for prostatic cancer were studied versus tumor stage and patients' age. Metastases into regional lymph nodes were the most frequent, while bony and visceral metastases ranked second and third, respectively. Age-related peculiarities of dissemination were identified. The data obtained do not support the traditional standpoint that bones are the most frequent sites of prostatic cancer dissemination.

Adenocarcinoma↗
PubMedDate not supplied

[The cardiovascular and thromboembolic complications of intravital estrogen therapy in middle-aged and elderly patients with prostatic cancer].

Cardiovascular and thromboembolic complications arising as a result of 1-16-year estrogen therapy were evaluated in 105 prostatic cancer patients. The incidence of the complications was higher in those who had pretreatment cardiological or vascular load. The latter caused death in half of the patients. Preventive and therapeutic measures to control the complications, prognosis signs are indicated.

Aged↗
PubMedDate not supplied

[The results of long-term permixon treatment in patients with symptoms of lower urinary tracts dysfunction due to benign prostatic hyperplasia].

The trial enrolled 155 patients (mean age 65 years) with documented benign prostatic hyperplasia and lower urinary tracts symptoms (LUTS) (IPSS > 6). All the patients received permixon in a dose 160 mg twice a day for 2 years. The data on 130 patients eligible for assessment were processed statistically by dynamics of IPSS, quality of life (QOL), index of sexual function (MSF-4), size of the prostate, urodynamic and biological parameters which were estimated in 6 (V6), 12 (V12), 18 (V18) and 24 months (V24). Clinical examination with registration of all side effects was made each 3 months. Permixon was found to noticeably reduce IPSS and QOL and increase maximal urine flow speed. The size of the prostate diminished insignificantly. Sexual function remained unchanged for 1 year and improved markedly within the second year (p = 0.001). Permixon had no effect on the level of prostate-specific antigen. Plasma hormones (testosterone, DHT, estradiol, LH, androstendion) did not change. Nine patients developed 10 side effects but they were unrelated to the treatment.

5-alpha Reductase Inhibitors↗